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The term sarcopenia was originally created
to refer age-related loss of muscle mass
with consequent loss of strength (Morley
et al., 2001). There are now four inter-
national definitions of sarcopenia (Cruz-
Jentoft et al., 2010; Muscaritoli et al.,
2010; Morley et al., 2011). In essence they
all agree, requiring a measure of walk-
ing capability [either low gait speed or
a limited endurance (distance) in a 6-
min walk], together with an appendicular
lean mass of <2 SDs of a sex and ethni-
cally corrected normal level for individu-
als 20–30 years old. Sarcopenia is a preva-
lent health problem among the elderly.
On average, 5–13 and 11–50% of people
aged 60−70 years and ≥80 years, respec-
tively suffer sarcopenia with higher preva-
lences (68%) been reported in nursing
home residents ≥70 years (Landi et al.,
2012).
Sarcopenia needs to be differentiated
from cachexia, which is a combination
of both muscle and fat loss and is usu-
ally attributable to an excess of catabolic
cytokines associated with a disease process
(Argiles et al., 2010). Sarcopenia is a prime
component of the frailty syndrome, and
both sarcopenia and frailty are associated
with increased disability, falls, hospitaliza-
tion, nursing home admission, and mor-
tality (Cesari and Vellas, 2012; Landi et al.,
2012).
Medical efforts to develop treatments
aiming at preventing aging sarcopenia as
well as acute muscle atrophy and frailty
in critical patients are considered a step
forward in public health. Several hormonal
therapies have been proposed for this pur-
pose, such as those based on human growth
hormone (hGH), IGF-1, testosterone, and
stanozolol. However, the secondary effects
associated with these therapies make it nec-
essary to find novel non-toxic and non-
hormonal therapies. In this way, elderly or
bedridden patients may improve muscle
function and decrease the degree of depen-
dence associated with these populations.
New drugs such as allopurinol or losartan
(Sanchis-Gomar et al., 2011), all of them
approved by the Food and Drugs Admin-
istration (FDA) and actually prescribed for
the treatment of other diseases, could be
useful in preventing loss of muscle mass in
the described susceptible populations yet
new pharmacological targets are needed.
NOVEL PHARMACOLOGICAL TARGETS
TO PREVENT SARCOPENIA: EMERGING
PATHWAYS TO BE EXPLORED
p16INK4a, NAD+, AND SESTRINS PATHWAYS
In a recent manuscript, we proposed
new targets for combating aging-related
chronic illness (Pareja-Galeano et al.,
2014). An altered mitochondrial home-
ostasis through reduced sirtuin 1 (SIRT1)
activity induced by low nicotinamide
adenine dinucleotide (NAD+) levels has
been recently advocated as a hallmark
of muscle aging. A depleted NAD+ pool
could be the result of both the dimin-
ished NAD+ synthesis and increased
NAD+ consumption that occurs with
age (Gomes et al., 2014). Treatment of
mice with NMN (an NAD+ precursor)
can restore NAD+ levels and markers of
mitochondrial function that decay with
age, reversing muscle mitochondrial senes-
cence (Prolla and Denu, 2014).
Another novel potential biomarker aris-
ing from recent animal research is the
p16INK4a tumor suppressor. In geriatric
mice, satellite cells lose their quiescent
state owing to deregulation of p16INK4a,
whereas repressing p16INK4a restores
muscle regenerative capacity (Sousa-Victor
et al., 2014). It is also known that
p16INK4a expression increases with age,
and its greater expression has been linked
to increased attrition (Tsygankov et al.,
2009). Recent evidence suggests that
p16INK4a mRNA expression in periph-
eral blood T-lymphocytes is upregulated
by gerontogenic behaviors such as tobacco
use and physical inactivity, pointing to
a critical role in age-related diseases
(Song et al., 2010).
Sestrins are a third recently discov-
ered hallmark of aging sarcopenia. Mam-
malian cells express sestrins (Sesn1, Sesn2,
and Sesn3) in response to stress includ-
ing DNA damage, oxidative stress, and
hypoxia. Sestrins can inhibit the activity of
the mammalian target of rapamycin com-
plex 1 (mTORC1) through activation of
AMP-dependent protein kinase (AMPK)
(Lee et al., 2013). Sestrins prevent sar-
copenia, insulin resistance, diabetes, and
obesity. They also extend life and health
span through activation of AMPK, sup-
pression of mTORC1, and stimulation of
autophagic signaling (Lee et al., 2013).
We also proposed a possible role of the
AMPK-modulating functions of sestrins in
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FIGURE 1 | Hypothesizing the role of FGF21-PGC-1α-Irisin axis in age-related conditions and
sarcopenia. See text for abbreviations.
the benefits produced by exercise in older
subjects (Sanchis-Gomar, 2013a).
FGF21 AND IRISIN: POTENTIAL THERAPEUTIC
PGC-1α-RELATED TARGETS FOR AGING AND
AGE-ASSOCIATED DISEASES
Circulating body levels of irisin and fibrob-
last growth factor 21 (FGF21) increase
after cold exposure (Lee et al., 2014).
Exercise-induced irisin secretion by work-
ing skeletal muscles, which could have
evolved from shivering-related muscle con-
traction, might be a potential target of
therapies designed to optimize weight con-
trol and metabolic profile (Lee et al.,
2014). Hence, targeting irisin and FGF21,
and particularly the key signaling mole-
cule responsible for their secretion, the
peroxisome proliferator-activated receptor
gamma coactivator-1 α (PGC-1α), could
identify new candidates to be included in
the anti-aging armamentarium (Sanchis-
Gomar, 2013b).
Irisin is an 112-amino acid glycopro-
tein, derived from the cleavage in working
muscles – and subsequent secretion to the
circulation – of a PGC-1α-dependent type
I membrane protein, the fibronectin type
III domain-containing protein 5 (FNDC5,
209 amino acids) (Bostrom et al., 2012).
Exercise-released irisin might act as a hor-
mone either locally within the muscle
or targeting distant organs, particularly
white adipose tissue, and increase total
energy expenditure (Bostrom et al., 2012).
Irisin production increases with chronic
endurance exercise in mice and humans,
and has been described to mitigate obe-
sity and diet-induced insulin resistance
(Bostrom et al., 2012), yet its levels
decline with age (Sanchis-Gomar and
Perez-Quilis, 2014). To explain exercise
benefits on insulin resistance, we recently
proposed the following pathway start-
ing in muscle and targeting pancreatic
β-cells: exercise-induced reactive oxygen
species (ROS)→ p38→MAPK→PGC-
1α→ irisin→ betatrophin→ β-cell re-
generation (Sanchis-Gomar and Perez-
Quilis, 2014). This pathway could also be
affected by aging. Interestingly, it has been
also recently reported that disease-free cen-
tenarians have increased serum irisin levels
(Emanuele et al., 2014). Exercise induces
the expression of another PGC-1α – related
hormone, FGF21 (Kim et al., 2013). Fast-
ing drives the production of FGF21 in the
liver, where it induces PGC-1α expression,
thereby stimulating fatty acid oxidation,
tricarboxylic acid cycle flux, and gluconeo-
genesis. In effect, mice lacking FGF21 are
unable to fully induce PGC-1α expression
in response to a prolonged fast and show
impaired gluconeogenesis and ketogenesis
(Potthoff et al., 2009). Thus, FGF21 plays
an important role in ensuring metabolic
regulation during progression from fasting
to starvation.
Besides metabolic deregulation and
increased insulin resistance, another
important consequence of the aging
process, reduced mitochondrial biogen-
esis, is also linked to abnormal PGC-1α
signaling (Sanchis-Gomar and Derbre,
2014). Importantly, an age-related lack of
muscle mitochondrial biogenesis can con-
tribute to sarcopenia. PGC-1α knock-out
mice and aged rats show a strikingly sim-
ilar muscle phenotype: they are unable to
express PGC-1α in response to the stim-
uli [i.e., exercise training, cold induction,
or thyroid hormone (triiodothyronine –
T3 – treatment)] that naturally up-regulate
this molecule in young healthy rats (Der-
bre et al., 2012). Thus, maintaining normal
PGC-1α responsiveness might help prevent
age-related lack of muscle mitochondr-
ial biogenesis (Derbre et al., 2012). In
fact, several PGC-1α activators such as
T3, cold induction, 5′-aminoimidazole-
4-carboxamide-1-beta-d-ribofuranoside
(AICAR), β-adrenergics, cytokines, and
exercise have been postulated to pre-
vent aging sarcopenia (Figure 1). The
pioneer results by Lee et al. (2014)
also suggest that targeting PGC-1α, e.g.,
using endocrine activators of brown
fat function such as irisin and FGF21,
might benefit the treatment of other age-
related conditions, particularly metabolic
diseases.
FREE-RADICAL THEORY OF AGING
QUESTIONED: OTHER MOLECULAR TARGETS
TO PREVENT SARCOPENIA ARE NEEDED
Treatments for age-related and disease-
related muscle loss might improve active
life expectancy in older people, and lead
to substantial health-care savings and
improved quality of life (Rastogi-Kalyani
et al., 2014). However, the results of recent
epidemiological studies (Perez et al., 2009)
suggest that antioxidant supplementation
does not lower the incidence of major age-
associated diseases and might even increase
the risk of death in some cases, have ques-
tioned the classic free-radical theory of
aging (Gladyshev, 2014; Sanchis-Gomar
et al., 2014). In fact, evidence mounts that
ROS are important mediators of the health-
promoting, life-span-extending capacity of
regular exercise, as they play an important
signaling role in a multitude of pathways
including: angiogenesis, vascular distensi-
bility, and up-regulation of PGC-1α, PGC-
1α/nuclear respiratory factor 1-stimulated
mitochondrial biogenesis or cytoprotective
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“stress proteins” (heme oxygenase 1, heat
shock proteins like HSP60 and HSP70) in
muscle (Fiuza-Luces et al., 2013; Sanchis-
Gomar and Derbre, 2014). This means that
antioxidant interventions are unlikely to
help combat sarcopenia. Moreover, anti-
ROS strategies could even aggravate sar-
copenia. Thus, a major switch in strat-
egy is proposed and investigators are
now focusing on myostatin and follistatin
as promising molecular targets of anti-
sarcopenia treatments. Myostatin is a skele-
tal muscle-specific secreted peptide, per-
taining to the transforming growth factor-
β (TGF-β) family member, that inhibits
myoblast proliferation and consequently
muscle mass/strength by acting as a neg-
ative regulator of mTOR-signaling (Garat-
achea et al., 2013). Mice treated with losar-
tan, an angiotensin II receptor antago-
nist, were protected against loss of mus-
cle mass and this effect was mediated by
activation of the IGF-1/Akt/mTOR path-
way (Sanchis-Gomar et al., 2011). These
observations highlight the importance of
IGF-1/GH balance in longevity and may be
of therapeutic interest when targeting the
undesirable effects of aging, especially at
the muscle level (Sandri et al., 2013).
Myostatin inhibition by agents capable
of blocking the myostatin signaling path-
way such as ACVR2B (a soluble form of
the activin type IIB receptor) could have
important applications in the treatment of
human muscle degenerative diseases (Lee
et al., 2005). In addition, the growth and
derived factor (GDF)-associated serum
proteins-1 (GASP-1) and 2 (GASP-2),
which show competitive binding with
proteins capable of inhibiting myostatin,
decrease muscle weight and impair mus-
cle regeneration ability in mice (Lee and
Lee, 2013). Moreover, the inhibition of
the myostatin/activin A signaling pathway
is sufficient to induce muscle hypertro-
phy and can be an effective therapeutic
approach for increasing muscle growth
in disease settings characterized by satel-
lite cell dysfunction. Finally, the propeptide
follistatin, a myostatin antagonist, might be
a useful agent for enhancing muscle growth
in human therapeutic applications. In fact,
increasing follistatin circulating concentra-
tions might help prevent and treat frailty, as






Another important tool in the preven-
tion of sarcopenia is physical exercise
(some of the molecular pathways involved
have been discussed above). Particularly,
exercise training programs with resistance
(strength) exercises (i.e., movements per-
formed against a specific external force
that is regularly increased during training)
are especially useful for improving muscle
mass or strength in the elderly (Liu and
Latham, 2009), including in the oldest-old
(people aged 90 years or over) (Fiatarone
et al., 1990).
On the other hand, autophagy also plays
an important key role both in the modu-
lation of lifespan and sarcopenia (Madeo
et al., 2010; Schiavi et al., 2013). Interest-
ingly, autophagy is required to maintain
muscle mass and thus to prevent sarcopenia
(Masiero et al., 2009; Neel et al., 2013). In
effect, failure of autophagy contributes to
the sarcopenic phenotype observed in pre-
mature aging (Joseph et al., 2013). For this
reason, physical exercise and calorie restric-
tion are commonly recommended to pre-
vent sarcopenia since both of them mod-
ulate autophagy signaling (Marzetti et al.,
2008; Wohlgemuth et al., 2010).
FINAL OPINION
As an essential step for the prevention
of aging-related diseases, and specifically,
sarcopenia, more basic research is needed
on the main cellular hallmarks of muscle
senescence. There is a plethora of potential
molecular signals that are candidates to be
targeted in future treatment strategies aim-
ing at combating sarcopenia, a devastating
effect of aging that is often overlooked.
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